Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study from Edith Cowan University (ECU) has shown that understanding the following motivations can help find personal goals and prevent dementia.
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
2.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
3.
Next Day Mood Is Affected by Ability to Recover From Work.
4.
MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy
5.
Cancer mortality continuing to decline, says report
1.
The Growing Crisis of Aplastic Anemia: A Call for Action
2.
Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms
3.
Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025
4.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
5.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Navigating the Complexities of Ph Negative ALL - Part II
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge